Literature DB >> 23071359

Predicting drug targets and biomarkers of cancer via genome-scale metabolic modeling.

Livnat Jerby1, Eytan Ruppin.   

Abstract

The metabolism of cancer cells is reprogrammed in various ways to support their growth and survival. Studying these phenomena to develop noninvasive diagnostic tools and selective treatments is a promising avenue. Metabolic modeling has recently emerged as a new way to study human metabolism in a systematic, genome-scale manner by using pertinent high-throughput omics data. This method has been shown in various studies to provide fairly accurate estimates of the metabolic phenotype and its modifications following genetic and environmental perturbations. Here, we provide an overview of genome-scale metabolic modeling and its current use to model human metabolism in health and disease. We then describe the initial steps made using it to study cancer metabolism and how it may be harnessed to enhance ongoing experimental efforts to identify drug targets and biomarkers for cancer in a rationale-based manner. ©2012 AACR

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23071359     DOI: 10.1158/1078-0432.CCR-12-1856

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  38 in total

1.  A kidney-specific genome-scale metabolic network model for analyzing focal segmental glomerulosclerosis.

Authors:  Salma Sohrabi-Jahromi; Sayed-Amir Marashi; Shiva Kalantari
Journal:  Mamm Genome       Date:  2016-02-29       Impact factor: 2.957

2.  Applications of a metabolic network model of mesenchymal stem cells for controlling cell proliferation and differentiation.

Authors:  Hamideh Fouladiha; Sayed-Amir Marashi; Mohammad Ali Shokrgozar; Mehdi Farokhi; Amir Atashi
Journal:  Cytotechnology       Date:  2017-10-04       Impact factor: 2.058

3.  Synthetic dosage lethality in the human metabolic network is highly predictive of tumor growth and cancer patient survival.

Authors:  Wout Megchelenbrink; Rotem Katzir; Xiaowen Lu; Eytan Ruppin; Richard A Notebaart
Journal:  Proc Natl Acad Sci U S A       Date:  2015-09-14       Impact factor: 11.205

Review 4.  Harnessing Big Data for Systems Pharmacology.

Authors:  Lei Xie; Eli J Draizen; Philip E Bourne
Journal:  Annu Rev Pharmacol Toxicol       Date:  2016-10-13       Impact factor: 13.820

Review 5.  An argument for mechanism-based statistical inference in cancer.

Authors:  Donald Geman; Michael Ochs; Nathan D Price; Cristian Tomasetti; Laurent Younes
Journal:  Hum Genet       Date:  2014-11-09       Impact factor: 4.132

6.  Genome-Scale Model-Based Identification of Metabolite Indicators for Early Detection of Kidney Toxicity.

Authors:  Venkat R Pannala; Kalyan C Vinnakota; Shanea K Estes; Irina Trenary; Tracy P OˈBrien; Richard L Printz; Jason A Papin; Jaques Reifman; Tatsuya Oyama; Masakazu Shiota; Jamey D Young; Anders Wallqvist
Journal:  Toxicol Sci       Date:  2020-02-01       Impact factor: 4.849

7.  Redundancy: a critical obstacle to improving cancer therapy.

Authors:  Orit Lavi
Journal:  Cancer Res       Date:  2015-01-09       Impact factor: 12.701

8.  Chromosome 3p loss of heterozygosity is associated with a unique metabolic network in clear cell renal carcinoma.

Authors:  Francesco Gatto; Intawat Nookaew; Jens Nielsen
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-18       Impact factor: 11.205

9.  Targeting cancer metabolism.

Authors:  Beverly A Teicher; W Marston Linehan; Lee J Helman
Journal:  Clin Cancer Res       Date:  2012-10-15       Impact factor: 12.531

10.  c-Myc and cancer metabolism.

Authors:  Donald M Miller; Shelia D Thomas; Ashraful Islam; David Muench; Kara Sedoris
Journal:  Clin Cancer Res       Date:  2012-10-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.